Back to Search
Start Over
Development of vaccines for Marburg hemorrhagic fever.
- Source :
-
Expert review of vaccines [Expert Rev Vaccines] 2007 Feb; Vol. 6 (1), pp. 57-74. - Publication Year :
- 2007
-
Abstract
- Marburg (MARV) and Ebola viruses (EBOV) emerged from the rainforests of Central Africa more than 30 years ago causing outbreaks of severe and, usually, fatal hemorrhagic fever. EBOV has garnered the lion's share of the attention, fueled by the higher frequency of EBOV outbreaks, high mortality rates and importation into the USA, documented in such popular works as the best-selling novel 'The Hot Zone'. However, recent large outbreaks of hundreds of cases of MARV infection in the Democratic Republic of the Congo and Angola with case fatalities approaching 90% dramatically highlight its lethal potential. Although no vaccines or antiviral drugs for MARV are currently available, remarkable progress has been made over the last few years in developing potential countermeasures against MARV in nonhuman primate models. In particular, a vaccine based on attenuated recombinant vesicular stomatitis virus was recently shown to have both preventive and postexposure efficacy.
- Subjects :
- Angola epidemiology
Animals
Democratic Republic of the Congo epidemiology
Disease Outbreaks prevention & control
Humans
Marburg Virus Disease epidemiology
Mass Vaccination methods
Mass Vaccination trends
Marburg Virus Disease prevention & control
Marburgvirus drug effects
Viral Vaccines chemical synthesis
Viral Vaccines therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1744-8395
- Volume :
- 6
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Expert review of vaccines
- Publication Type :
- Academic Journal
- Accession number :
- 17280479
- Full Text :
- https://doi.org/10.1586/14760584.6.1.57